Recent Comments

Comment RSS

Search results for 'Esomeprazole'


Teva Pharmaceutical Industries enters into two definitive agreements with AstraZeneca Teva Pharmaceutical Industries Ltd. announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages. http://www.news-medical.net/news/20100107/Teva-Pharmaceutical-Industries-enters-into-two-definitive-agreements-with-AstraZeneca.aspx
FDA: Plavix-Prilosec combination may reduce anti-clotting effect Patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC (omeprazole) with the anti-clotting drug Plavix (clopidogrel), the U.S. Food and Drug Administration warned on Nov. 17. http://www.news-medical.net/news/20091119/FDA-Plavix-Prilosec-combination-may-reduce-anti-clotting-effect.aspx
AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA. http://www.news-medical.net/news/20091020/AstraZeneca-and-POZEN-announce-the-pivotal-data-from-two-POZEN-clinical-trials.aspx
New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400). http://www.news-medical.net/news/20090831/New-Drug-Application-for-VIMOVO-accepted-by-US-Food-and-Drug-Administration.aspx
Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions. http://www.news-medical.net/news/2009/05/06/49238.aspx
PPI prescribed for asthma ineffective and too expensive According to researchers in the U.S. millions of asthma patients taking the drug Nexium, (esomeprazole), or a similar drug are doing so unnecessarily. http://www.news-medical.net/news/2009/04/13/48249.aspx
Treatment for acid reflux does not improve asthma symptoms A commonly used treatment for acid reflux does not improve asthma symptoms or control in patients who do not have symptoms of gastroesophageal reflux (GER), according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and by the American Lung Association (ALA). http://www.news-medical.net/news/2009/04/12/48191.aspx
Prescription heartburn medications do not ease asthma symptoms The predominance of heartburn among asthma sufferers led many specialists to suspect that acid reflux could be a trigger for the coughing, wheezing and breathlessness of asthma. http://www.news-medical.net/news/2009/04/09/48153.aspx
National study results change common method of treating asthma A nationwide study of adults with asthma reveals no benefit for treatment for silent acid reflux, which long has been thought to be the culprit for some severe asthma symptoms such as coughing, wheezing and breathlessness. http://www.news-medical.net/news/2009/04/08/48132.aspx
Is esomeprazole the best choice for reflux esophagitis patients? In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors (PPIs). http://www.news-medical.net/news/2009/04/02/47854.aspx
Is esomeprazole the best choice for reflux esophagitis patients? In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors (PPIs). http://www.news-medical.net/news/2009/03/03/46434.aspx
AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium) AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old. http://www.news-medical.net/news/2008/12/21/44455.aspx
FDA approves Nexium for gastroesophageal reflux disease in children The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). http://www.news-medical.net/news/2008/02/28/35751.aspx
Ranbaxy receives tentative approval for Esomeprazole Magnesium delayed-release capsules Ranbaxy Laboratories Limited has announced that it has received tentative approval from the U.S. Food and Drug Administration for Esomeprazole Magnesium Delayed-Release Capsules, 20 mg (base) and 40 mg (base). http://www.news-medical.net/news/2008/02/08/35089.aspx
FDA taking no chances when it comes to drug safety These days the U.S. Food and Drug Administration (FDA) is taking no chances when it comes to the safety of new drugs. http://www.news-medical.net/news/2007/08/13/28725.aspx
Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS Esomeprazole magnesium can reduce the incidence of gastric (stomach) ulcers in patients at risk of developing gastric ulcers and who regularly take either non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs http://www.news-medical.net/news/2006/03/30/16973.aspx
AstraZeneca starts patent infringement litigation against IVAX AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals and Zenith Laboratories http://www.news-medical.net/news/2006/03/08/16453.aspx
Treating nighttime heartburn improves sleep and boosts quality of life The first major multi-center, randomized, double-blind, placebo-controlled trial addressing therapy for gastroesophageal reflux disease (GERD) related sleep disorders is published in the September issue of The American Journal of Gastroenterology. http://www.news-medical.net/news/2005/09/01/12884.aspx
Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure. http://www.news-medical.net/news/2005/01/20/7412.aspx
Canadian Rheumatology Association issues statement on Vioxx alternatives The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week. http://www.news-medical.net/news/2004/10/07/5402.aspx
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.